{"id":627756,"date":"2022-11-29T16:24:02","date_gmt":"2022-11-29T16:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=627756"},"modified":"2022-11-29T16:24:02","modified_gmt":"2022-11-29T16:24:02","slug":"polycystic-ovarian-syndrome-pcos-market-to-exhibit-substantial-growth-rate-during-the-forecast-period-202232-key-players-zydus-discovery-spruce-biosciences-kindex-pharma-abbvie","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/polycystic-ovarian-syndrome-pcos-market-to-exhibit-substantial-growth-rate-during-the-forecast-period-202232-key-players-zydus-discovery-spruce-biosciences-kindex-pharma-abbvie_627756.html","title":{"rendered":"Polycystic Ovarian Syndrome (PCOS) Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-32) | Key Players – Zydus Discovery, Spruce Biosciences, Kindex Pharma, AbbVie"},"content":{"rendered":"
\n
\"Polycystic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Polycystic Ovarian Syndrome (PCOS) Market is expected to grow in the coming years owing to the increase in the prevalence of Polycystic Ovarian Syndrome, along with the expected launch of pipeline therapies in the market.<\/div>\n

DelveInsight’s “Polycystic Ovarian Syndrome (PCOS) Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Polycystic Ovarian Syndrome market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Polycystic Ovarian Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Polycystic<\/p>\n

Polycystic Ovarian Syndrome (PCOS): An Overview<\/strong><\/p>\n

Polycystic ovary syndrome (PCOS) is a heterogeneous disorder characterized by hyperandrogenism and chronic anovulation. PCOS is characterized by excessive ovarian and\/or adrenal androgen secretion. Intrinsic ovarian factors, such as altered steroidogenesis, and factors external to the ovary, such as hyperinsulinemia, contribute to excessive ovarian androgen production.<\/p>\n

Characteristic features include more growing follicles in women with PCOS compared with normal controls with premature growth arrest of antral follicles at 5 to 8 mm. The classic ovarian phenotype of enlarged ovaries with string-of-pearl morphology and theca interstitial hyperplasia reflects androgen exposure; this morphology has also been observed in women with congenital adrenal hyperplasia (CAH) and female-to-male transgender individuals. Both genetic and lifestyle factors contribute to the development of the PCOS phenotype. <\/em><\/p>\n

Polycystic Ovarian Syndrome (PCOS) Market Key Facts<\/strong><\/p>\n